BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Turner PM, Turner TJ. Validation of the crisis triage rating scale for psychiatric emergencies. Can J Psychiatry. 1991;36:651-654. [PMID: 1773400 DOI: 10.1136/gut.51.4.459] [Cited by in Crossref: 76] [Cited by in F6Publishing: 74] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Tohme S, Geller DA, Cardinal JS, Chen HW, Packiam V, Reddy S, Steel J, Marsh JW, Tsung A. Radiofrequency ablation compared to resection in early-stage hepatocellular carcinoma. HPB (Oxford). 2013;15:210-217. [PMID: 23374361 DOI: 10.1111/j.1477-2574.2012.00541.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 3.2] [Reference Citation Analysis]
2 Suzuki E, Furuse J, Ikeda M, Ishii H, Okusaka T, Nakachi K, Mitsunaga S, Ueno H, Morizane C. A Phase I/II Study of Combined Chemotherapy with Mitoxantrone and Uracil/Tegafur for Advanced Hepatocellular Carcinoma. Japanese Journal of Clinical Oncology 2011;41:328-33. [DOI: 10.1093/jjco/hyq219] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
3 Ho P, Chou C, Kuo Y, Tu L, Yeh S. Taiwanin A induced cell cycle arrest and p53-dependent apoptosis in human hepatocellular carcinoma HepG2 cells. Life Sciences 2007;80:493-503. [DOI: 10.1016/j.lfs.2006.10.017] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
4 Niu LZ, Li JL, Zeng JY, Mu F, Liao MT, Yao F, Li L, Liu CY, Chen JB, Zuo JS, Xu KC. Combination treatment with comprehensive cryoablation and immunotherapy in metastatic hepatocellular cancer. World J Gastroenterol 2013; 19(22): 3473-3480 [PMID: 23801841 DOI: 10.3748/wjg.v19.i22.3473] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
5 Ren S, Li C, Dai Y, Li N, Wang X, Tian F, Zhou S, Qiu Z, Lu Y, Zhao D. Comparison of pharmacokinetics, tissue distribution and pharmacodynamics of liposomal and free doxorubicin in tumour-bearing mice following intratumoral injection. J Pharm Pharmacol. 2014;66:1231-1239. [PMID: 24716458 DOI: 10.1111/jphp.12257] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
6 Vivarelli M, Guglielmi A, Ruzzenente A, Cucchetti A, Bellusci R, Cordiano C, Cavallari A. Surgical resection versus percutaneous radiofrequency ablation in the treatment of hepatocellular carcinoma on cirrhotic liver. Ann Surg. 2004;240:102-107. [PMID: 15213625 DOI: 10.1097/01.sla.0000129672.51886.44] [Cited by in Crossref: 178] [Cited by in F6Publishing: 158] [Article Influence: 9.9] [Reference Citation Analysis]
7 Takahashi A, Yamamoto Y, Yasunaga M, Koga Y, Kuroda J, Takigahira M, Harada M, Saito H, Hayashi T, Kato Y, Kinoshita T, Ohkohchi N, Hyodo I, Matsumura Y. NC-6300, an epirubicin-incorporating micelle, extends the antitumor effect and reduces the cardiotoxicity of epirubicin. Cancer Sci 2013;104:920-5. [PMID: 23495762 DOI: 10.1111/cas.12153] [Cited by in Crossref: 82] [Cited by in F6Publishing: 65] [Article Influence: 9.1] [Reference Citation Analysis]
8 Xu XS, Qu K, Liu C, Zhang YL, Liu J, Song YZ, Zhang P, Liu SN, Chang HL. Highlights for α-fetoprotein in determining prognosis and treatment monitoring for hepatocellular carcinoma. World J Gastroenterol 2012; 18(48): 7242-7250 [PMID: 23326129 DOI: 10.3748/wjg.v18.i48.7242] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
9 Yeo W, Lam K, Zee B, Chan P, Mo F, Ho W, Wong W, Leung T, Chan A, Ma B, Mok T, Johnson P. Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Annals of Oncology 2004;15:1661-6. [DOI: 10.1093/annonc/mdh430] [Cited by in Crossref: 123] [Cited by in F6Publishing: 116] [Article Influence: 6.8] [Reference Citation Analysis]
10 Song J, Wang Y, Teng M, Zhang S, Yin M, Lu J, Liu Y, Lee RJ, Wang D, Teng L. Cordyceps militaris induces tumor cell death via the caspase‑dependent mitochondrial pathway in HepG2 and MCF‑7 cells. Mol Med Rep 2016;13:5132-40. [PMID: 27109250 DOI: 10.3892/mmr.2016.5175] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
11 Cao H, Chen X, Wang Z, Wang L, Xia Q, Zhang W. The role of MDM2-p53 axis dysfunction in the hepatocellular carcinoma transformation. Cell Death Discov 2020;6:53. [PMID: 32595984 DOI: 10.1038/s41420-020-0287-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 5.5] [Reference Citation Analysis]
12 Xu SP, Sun GP, Shen YX, Wei W, Peng WR, Wang H. Antiproliferation and apoptosis induction of paeonol in HepG2 cells. World J Gastroenterol 2007; 13(2): 250-256 [PMID: 17226904 DOI: 10.3748/wjg.v13.i2.250] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 39] [Article Influence: 2.3] [Reference Citation Analysis]
13 Towner RA, Smith N, Tesiram YA, Abbott A, Saunders D, Blindauer R, Herlea O, Silasi-mansat R, Lupu F. In Vivo Detection of c-MET Expression in a Rat Hepatocarcinogenesis Model Using Molecularly Targeted Magnetic Resonance Imaging. Mol Imaging 2007;6:7290.2006.00031. [DOI: 10.2310/7290.2006.00031] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
14 Huang C, Sheng S, Sun X, Liu J, Huang G. Lens culinaris agglutinin-reactive α-fetoprotein decline after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma predicts survival. Clin Chim Acta. 2014;431:232-238. [PMID: 24565960 DOI: 10.1016/j.cca.2014.02.009] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
15 Lange N, Tontsa AT, Wegscheid C, Mkounga P, Nkengfack AE, Loscher C, Sass G, Tiegs G. The Limonoids TS3 and Rubescin E Induce Apoptosis in Human Hepatoma Cell Lines and Interfere with NF-κB Signaling. PLoS One 2016;11:e0160843. [PMID: 27518192 DOI: 10.1371/journal.pone.0160843] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
16 Pourgholami MH, Morris DL. 1,25-Dihydroxyvitamin D3 in lipiodol for the treatment of hepatocellular carcinoma: cellular, animal and clinical studies. J Steroid Biochem Mol Biol. 2004;89-90:513-518. [PMID: 15225830 DOI: 10.1016/j.jsbmb.2004.03.065] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
17 Mu F, Niu L, Li H, Liao M, Li L, Liu C, Chen J, Li J, Zuo J, Xu K. Percutaneous comprehensive cryoablation for metastatic hepatocellular cancer. Cryobiology. 2013;66:76-80. [PMID: 23237910 DOI: 10.1016/j.cryobiol.2012.11.008] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
18 Li HG, Xie DR, Shen XM, Li HH, Zeng H, Zeng YJ. Clinicopathological significance of expression of paxillin, syndecan-1 and EMMPRIN in hepatocellular carcinoma. World J Gastroenterol 2005; 11(10): 1445-1451 [PMID: 15770719 DOI: 10.3748/wjg.v11.i10.1445] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 43] [Article Influence: 2.6] [Reference Citation Analysis]
19 Montorsi M, Santambrogio R, Bianchi P, Donadon M, Moroni E, Spinelli A, Costa M. Survival and recurrences after hepatic resection or radiofrequency for hepatocellular carcinoma in cirrhotic patients: a multivariate analysis. J Gastrointest Surg. 2005;9:62-67; discussion 67-68. [PMID: 15623446 DOI: 10.1016/j.gassur.2004.10.003] [Cited by in Crossref: 87] [Cited by in F6Publishing: 83] [Article Influence: 5.1] [Reference Citation Analysis]
20 Azad A, Chionh F, Cebon J. Targeted agents for the systemic treatment of advanced hepatocellular carcinoma. Asia-Pacific Journal of Clinical Oncology 2009;5:76-86. [DOI: 10.1111/j.1743-7563.2009.01202.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
21 Pourgholami MH, Lu Y, Wang L, Stephens RW, Morris DL. Regression of Novikoff rat hepatocellular carcinoma following locoregional administration of a novel formulation of clofazimine in lipiodol. Cancer Letters 2004;207:37-47. [DOI: 10.1016/j.canlet.2003.11.019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
22 Saw MM, Kurz P, Agorastos N, Hor TA, Sundram FX, Yan YK, Alberto R. Complexes with the fac-{M(CO)3}+ (M=99mTc, Re) moiety and long alkyl chain ligands as Lipiodol surrogates. Inorganica Chimica Acta 2006;359:4087-94. [DOI: 10.1016/j.ica.2006.04.023] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
23 Lencioni R, Crocetti L. Image-guided thermal ablation of hepatocellular carcinoma. Critical Reviews in Oncology/Hematology 2008;66:200-7. [DOI: 10.1016/j.critrevonc.2008.01.003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
24 Testa R, Testa E, Giannini E, Botta F, Malfatti F, Chiarbonello B, Fumagalli A, Polegato S, Podesta E, Romagnoli P. Trans-catheter arterial chemoembolisation for hepatocellular carcinoma in patients with viral cirrhosis: role of combined staging systems, Cancer Liver Italian Program (CLIP) and Model for End-stage Liver Disease (MELD), in predicting outcome after treatment. Aliment Pharmacol Ther. 2003;17:1563-1569. [PMID: 12823161 DOI: 10.1046/j.1365-2036.2003.01647.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 2.2] [Reference Citation Analysis]
25 Zhao J, Dong L, Lu B, Wu G, Xu D, Chen J, Li K, Tong X, Dai J, Yao S. Down-regulation of osteopontin suppresses growth and metastasis of hepatocellular carcinoma via induction of apoptosis. Gastroenterology. 2008;135:956-968. [PMID: 18555021 DOI: 10.1053/j.gastro.2008.05.025] [Cited by in Crossref: 91] [Cited by in F6Publishing: 94] [Article Influence: 6.5] [Reference Citation Analysis]
26 Zhang EL, Liang BY, Chen XP, Huang ZY. Severity of liver cirrhosis: a key role in the selection of surgical modality for Child-Pugh A hepatocellular carcinoma. World J Surg Oncol. 2015;13:148. [PMID: 25879526 DOI: 10.1186/s12957-015-0567-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
27 Lum CT, Yang ZF, Li HY, Wai-yin Sun R, Fan ST, Poon RTP, Lin MC, Che C, Kung HF. Gold(III) compound is a novel chemocytotoxic agent for hepatocellular carcinoma. Int J Cancer 2006;118:1527-38. [DOI: 10.1002/ijc.21484] [Cited by in Crossref: 64] [Cited by in F6Publishing: 59] [Article Influence: 3.8] [Reference Citation Analysis]
28 Liao X, Wei J, Li Y, Zhong J, Liu Z, Liao S, Li Q, Wei C. 18F-FDG PET with or without CT in the diagnosis of extrahepatic metastases or local residual/recurrent hepatocellular carcinoma. Medicine (Baltimore). 2018;97:e11970. [PMID: 30142825 DOI: 10.1097/md.0000000000011970] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
29 Fan X, Du H, Sun Y, Jiang J, Wang Z, Yin W, Fan K, Li H. Suppression of the Wnt signaling pathway may contribute to the inhibition of proliferation of human hepatocellular carcinoma SMMC-7721 cells by esculetin. Oncol Lett 2017;14:1731-6. [PMID: 28789402 DOI: 10.3892/ol.2017.6364] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
30 Xu S, Sun G, Shen Y, Peng W, Wang H, Wei W. Synergistic effect of combining paeonol and cisplatin on apoptotic induction of human hepatoma cell lines. Acta Pharmacologica Sinica 2007;28:869-78. [DOI: 10.1111/j.1745-7254.2007.00564.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
31 Damdinsuren B, Nagano H, Sakon M, Kondo M, Yamamoto T, Umeshita K, Dono K, Nakamori S, Monden M. Interferon-? Is More Potent Than Interferon-? in Inhibition of Human Hepatocellular Carcinoma Cell Growth When Used Alone and in Combination With Anticancer Drugs. Ann Surg Oncol 2003;10:1184-90. [DOI: 10.1245/aso.2003.03.010] [Cited by in Crossref: 44] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
32 Abdel-Hamid NM, Nazmy MH, Mahmoud AW, Fawzy MA, Youssof M. A survey on herbal management of hepatocellular carcinoma. World J Hepatol 2011; 3(7): 175-183 [PMID: 21866249 DOI: 10.4254/wjh.v3.i7.175] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
33 Zhong J, Xiang B, Ma L, Li L. Conventional oral systemic chemotherapy for postoperative hepatocellular carcinoma: A systematic review. Mol Clin Oncol 2014;2:1091-6. [PMID: 25279203 DOI: 10.3892/mco.2014.337] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
34 Ali AM, Lizhi N, Jialiang L, Fei Y, Yuan W, Jianying Z, Jin Y, Jibing C, Feng M, Kecheng X. Cryoprotective therapy for hepatocellular carcinoma: study of 51 patients with a single lesion. Cryobiology. 2014;69:61-67. [PMID: 24859156 DOI: 10.1016/j.cryobiol.2014.05.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
35 Damdinsuren B, Nagano H, Monden M. Combined intra-arterial 5-fluorouracil and subcutaneous interferon-alpha therapy for highly advanced hepatocellular carcinoma. Hepatol Res 2007;37 Suppl 2:S238-50. [PMID: 17877489 DOI: 10.1111/j.1872-034X.2007.00191.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
36 Gan Q, Shao J, Cao Y, Lei J, Xie P, Ge J, Hu G. USP33 regulates c-Met expression by deubiquitinating SP1 to facilitate metastasis in hepatocellular carcinoma. Life Sci 2020;261:118316. [PMID: 32835698 DOI: 10.1016/j.lfs.2020.118316] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Zhao J, Zhang X, Shi M, Xu H, Jin J, Ni H, Yang S, Dai J, Wu M, Guo Y. TIP30 inhibits growth of HCC cell lines and inhibits HCC xenografts in mice in combination with 5-FU. Hepatology 2006;44:205-15. [PMID: 16799960 DOI: 10.1002/hep.21213] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
38 Yeo W, Mok TS, Zee B, Leung TW, Lai PB, Lau WY, Koh J, Mo FK, Yu SC, Chan AT, Hui P, Ma B, Lam KC, Ho WM, Wong HT, Tang A, Johnson PJ. A randomized phase III study of doxorubicin vs cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst. 2005;97:1532-1538. [PMID: 16234567 DOI: 10.1093/jnci/dji315] [Cited by in Crossref: 406] [Cited by in F6Publishing: 376] [Article Influence: 23.9] [Reference Citation Analysis]
39 Lou CY, Feng YM, Qian AR, Li Y, Tang H, Shang P, Chen ZN. Establishment and characterization of human hepatocellular carcinoma cell line FHCC-98. World J Gastroenterol 2004; 10(10): 1462-1465 [PMID: 15133854 DOI: 10.3748/wjg.v10.i10.1462] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
40 Li JK, Liu XH, Cui H, Xie XH. Radiofrequency ablation vs. surgical resection for resectable hepatocellular carcinoma: A systematic review and meta-analysis. Mol Clin Oncol 2020;12:15-22. [PMID: 31814972 DOI: 10.3892/mco.2019.1941] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
41 Tang PM, Zhang DM, Xuan NH, Tsui SK, Waye MM, Kong SK, Fong WP, Fung KP. Photodynamic therapy inhibits P-glycoprotein mediated multidrug resistance via JNK activation in human hepatocellular carcinoma using the photosensitizer pheophorbide a. Mol Cancer 2009;8:56. [PMID: 19646254 DOI: 10.1186/1476-4598-8-56] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 3.4] [Reference Citation Analysis]
42 Young JY, Rhee TK, Atassi B, Gates VL, Kulik L, Mulcahy MF, Larson AC, Ryu RK, Sato KT, Lewandowski RJ. Radiation dose limits and liver toxicities resulting from multiple yttrium-90 radioembolization treatments for hepatocellular carcinoma. J Vasc Interv Radiol. 2007;18:1375-1382. [PMID: 18003987 DOI: 10.1016/j.jvir.2007.07.016] [Cited by in Crossref: 80] [Cited by in F6Publishing: 73] [Article Influence: 5.7] [Reference Citation Analysis]
43 Salem R, Lewandowski RJ, Atassi B, Gordon SC, Gates VL, Barakat O, Sergie Z, Wong CY, Thurston KG. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol. 2005;16:1627-1639. [PMID: 16371529 DOI: 10.1097/01.rvi.0000184594.01661.81] [Cited by in Crossref: 294] [Cited by in F6Publishing: 69] [Article Influence: 18.4] [Reference Citation Analysis]
44 Lupo L, Panzera P, Giannelli G, Memeo M, Gentile A, Memeo V. Single hepatocellular carcinoma ranging from 3 to 5 cm: radiofrequency ablation or resection? HPB (Oxford). 2007;9:429-434. [PMID: 18345289 DOI: 10.1080/13651820701713758] [Cited by in Crossref: 60] [Cited by in F6Publishing: 60] [Article Influence: 5.0] [Reference Citation Analysis]
45 Schwartz M, Roayaie S, Konstadoulakis M. Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol. 2007;4:424-432. [PMID: 17597707 DOI: 10.1038/ncponc0844] [Cited by in Crossref: 191] [Cited by in F6Publishing: 179] [Article Influence: 12.7] [Reference Citation Analysis]
46 Crocetti L, Lencioni R. Thermal ablation of hepatocellular carcinoma. Cancer Imaging 2008;8:19-26. [PMID: 18331969 DOI: 10.1102/1470-7330.2008.0004] [Cited by in Crossref: 44] [Cited by in F6Publishing: 33] [Article Influence: 3.1] [Reference Citation Analysis]
47 Kim SJ, Seo HY, Choi JG, Sul HR, Sung HJ, Park KH, Choi IK, Oh SC, Yoon SY, Seo JH. Phase II study with a combination of epirubicin, cisplatin, UFT, and leucovorin in advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2006;57:436-442. [PMID: 16049620 DOI: 10.1007/s00280-005-0067-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
48 Grieco A, Pompili M, Caminiti G, Miele L, Covino M, Alfei B, Rapaccini GL, Gasbarrini G. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut 2005;54:411-8. [PMID: 15710992 DOI: 10.1136/gut.2004.048124] [Cited by in Crossref: 173] [Cited by in F6Publishing: 162] [Article Influence: 10.2] [Reference Citation Analysis]
49 Lu Y, Ma J, Lin J, Tian Y, Ma Y, Wang W, Li J, Zhang H, Jiao P. Cell membrane breakage and triggering T cell infiltration are involved in human telomerase reverse transcriptase (hTERT) promoter-driven novel peptide KK-64 for liver cancer gene therapy. Bioengineered 2021;12:12708-21. [PMID: 34898368 DOI: 10.1080/21655979.2021.2010314] [Reference Citation Analysis]
50 Nowak AK, Chow PK, Findlay M. Systemic therapy for advanced hepatocellular carcinoma: a review. Eur J Cancer. 2004;40:1474-1484. [PMID: 15196530 DOI: 10.1016/j.ejca.2004.02.027] [Cited by in Crossref: 134] [Cited by in F6Publishing: 114] [Article Influence: 7.4] [Reference Citation Analysis]
51 Sun GP, Wang H, Xu SP, Shen YX, Wu Q, Chen ZD, Wei W. Anti-tumor effects of paeonol in a HepA-hepatoma bearing mouse model via induction of tumor cell apoptosis and stimulation of IL-2 and TNF-alpha production. Eur J Pharmacol 2008;584:246-52. [PMID: 18329639 DOI: 10.1016/j.ejphar.2008.02.016] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 3.5] [Reference Citation Analysis]
52 Unitt E, Marshall A, Gelson W, Rushbrook SM, Davies S, Vowler SL, Morris LS, Coleman N, Alexander GJ. Tumour lymphocytic infiltrate and recurrence of hepatocellular carcinoma following liver transplantation. J Hepatol. 2006;45:246-253. [PMID: 16580084 DOI: 10.1016/j.jhep.2005.12.027] [Cited by in Crossref: 161] [Cited by in F6Publishing: 151] [Article Influence: 10.1] [Reference Citation Analysis]
53 Yeo W, Mo F, Koh J, Chan A, Leung T, Hui P, Chan L, Tang A, Lee J, Mok T, Lai P, Johnson P, Zee B. Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. Annals of Oncology 2006;17:1083-9. [DOI: 10.1093/annonc/mdl065] [Cited by in Crossref: 79] [Cited by in F6Publishing: 75] [Article Influence: 4.9] [Reference Citation Analysis]
54 Perumal A, AlSalhi MS, Kanakarajan S, Devanesan S, Selvaraj R, Tamizhazhagan V. Phytochemical evaluation and anticancer activity of rambutan (Nephelium lappaceum) fruit endocarp extracts against human hepatocellular carcinoma (HepG-2) cells. Saudi J Biol Sci 2021;28:1816-25. [PMID: 33732067 DOI: 10.1016/j.sjbs.2020.12.027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
55 Jin C, Li H, He Y, He M, Bai L, Cao Y, Song W, Dou K. Combination chemotherapy of doxorubicin and paclitaxel for hepatocellular carcinoma in vitro and in vivo. J Cancer Res Clin Oncol. 2010;136:267-274. [PMID: 19693537 DOI: 10.1007/500432-009-0658-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
56 Higashi T, Hatano E, Ikai I, Nishii R, Nakamoto Y, Ishizu K, Suga T, Kawashima H, Togashi K, Seo S, Kitamura K, Takada Y, Kamimoto S. FDG PET as a prognostic predictor in the early post-therapeutic evaluation for unresectable hepatocellular carcinoma. Eur J Nucl Med Mol Imaging 2010;37:468-82. [DOI: 10.1007/s00259-009-1284-9] [Cited by in Crossref: 45] [Cited by in F6Publishing: 35] [Article Influence: 3.5] [Reference Citation Analysis]
57 Huang D, Du X, Yuan R, Chen L, Liu T, Wen C, Huang M, Li M, Hao L, Shao J. Rock2 promotes the invasion and metastasis of hepatocellular carcinoma by modifying MMP2 ubiquitination and degradation. Biochemical and Biophysical Research Communications 2014;453:49-56. [DOI: 10.1016/j.bbrc.2014.09.061] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
58 Chunhu Z, Suiyu H, Meiqun C, Guilin X, Yunhui L. Antiproliferative and apoptotic effects of paeonol on human hepatocellular carcinoma cells. Anti-Cancer Drugs 2008;19:401-9. [DOI: 10.1097/cad.0b013e3282f7f4eb] [Cited by in Crossref: 23] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
59 Wang Y, Lee CG. Role of miR-224 in hepatocellular carcinoma: a tool for possible therapeutic intervention? Epigenomics. 2011;3:235-243. [PMID: 22122284 DOI: 10.2217/epi.11.5] [Cited by in Crossref: 31] [Cited by in F6Publishing: 35] [Article Influence: 3.1] [Reference Citation Analysis]
60 Bolondi L. Screening for hepatocellular carcinoma in cirrhosis. Journal of Hepatology 2003;39:1076-84. [DOI: 10.1016/s0168-8278(03)00349-0] [Cited by in Crossref: 135] [Cited by in F6Publishing: 49] [Article Influence: 7.1] [Reference Citation Analysis]
61 Jin C, Li H, He Y, He M, Bai L, Cao Y, Song W, Dou K. Combination chemotherapy of doxorubicin and paclitaxel for hepatocellular carcinoma in vitro and in vivo. J Cancer Res Clin Oncol 2010;136:267-74. [DOI: 10.1007/s00432-009-0658-5] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 2.8] [Reference Citation Analysis]
62 Treiber G, Wex T, Röcken C, Fostitsch P, Malfertheiner P. Impact of biomarkers on disease survival and progression in patients treated with octreotide for advanced hepatocellular carcinoma. J Cancer Res Clin Oncol 2006;132:699-708. [PMID: 16835748 DOI: 10.1007/s00432-006-0118-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
63 Chan SL, Mo FK, Johnson PJ, Hui EP, Ma BB, Ho WM, Lam KC, Chan AT, Mok TS, Yeo W. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol. 2009;27:446-452. [PMID: 19064965 DOI: 10.1200/jco.2008.18.8151] [Cited by in Crossref: 168] [Cited by in F6Publishing: 81] [Article Influence: 12.0] [Reference Citation Analysis]
64 Yeo W, Mo FK, Chan SL, Leung NW, Hui P, Lam WY, Mok TS, Lam KC, Ho WM, Koh J, Tang JW, Chan AT, Chan PK. Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy. Hepatology 2007;45:1382-9. [PMID: 17539025 DOI: 10.1002/hep.21572] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 3.1] [Reference Citation Analysis]
65 Helmberger T, Dogan S, Straub G, Schrader A, Jüngst C, Reiser M, Waggershauser T, Jakobs T, Hoffmann R, Löhe F, Graeb C, Rau H, Schauer R, Jauch K, Caselmann WH, Göke B, Jüngst D. Liver Resection or Combined Chemoembolization and Radiofrequency Ablation Improve Survival in Patients with Hepatocellular Carcinoma. Digestion 2007;75:104-12. [DOI: 10.1159/000104730] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
66 Golla K, Epstein JB, Cabay RJ. Liver disease: Current perspectives on medical and dental management. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology 2004;98:516-21. [DOI: 10.1016/j.tripleo.2004.09.011] [Cited by in Crossref: 22] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
67 Lee TK, Man K, Ho JW, Sun CK, Ng KT, Wang XH, Wong YC, Ng IO, Xu R, Fan ST. FTY720 induces apoptosis of human hepatoma cell lines through PI3-K-mediated Akt dephosphorylation. Carcinogenesis 2004;25:2397-405. [DOI: 10.1093/carcin/bgh250] [Cited by in Crossref: 63] [Cited by in F6Publishing: 56] [Article Influence: 3.5] [Reference Citation Analysis]
68 Alnaggar M, Niu L, Li J, Yao F, Wang Y, Zeng J, Ye J, Chen J, Mu F, Xu K. Cryoprotective therapy for huge hepatocellular carcinoma: a study of 14 patients with a single lesion. Cryobiology. 2014;69:457-461. [PMID: 25445461 DOI: 10.1016/j.cryobiol.2014.10.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
69 Ogasawara S, Yano H, Momosaki S, Akiba J, Nishida N, Kojiro S, Moriya F, Ishizaki H, Kuratomi K, Kojiro M. Growth inhibitory effects of IFN-beta on human liver cancer cells in vitro and in vivo. J Interferon Cytokine Res 2007;27:507-16. [PMID: 17572015 DOI: 10.1089/jir.2007.0183] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
70 Thomas MB, O’Beirne JP, Furuse J, Chan AT, Abou-Alfa G, Johnson P. Systemic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy. Ann Surg Oncol. 2008;15:1008-1014. [PMID: 18236117 DOI: 10.1245/s10434-007-9705-0] [Cited by in Crossref: 79] [Cited by in F6Publishing: 77] [Article Influence: 5.6] [Reference Citation Analysis]
71 Chan SL, Chan AT, Yeo W. Role of alpha-fetoprotein in hepatocellular carcinoma: prognostication, treatment monitoring or both? Future Oncol. 2009;5:889-899. [PMID: 19663737 DOI: 10.2217/fon.09.64] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
72 Martins A, Cortez-Pinto H, Marques-Vidal P, Mendes N, Silva S, Fatela N, Glória H, Marinho R, Távora I, Ramalho F. Treatment and prognostic factors in patients with hepatocellular carcinoma. Liver Int. 2006;26:680-687. [PMID: 16842324 DOI: 10.1111/j.1478-3231.2006.001285.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 2.5] [Reference Citation Analysis]
73 Takahashi N, Yoshida Y, Sugiura T, Matsuno K, Fujino A, Yamashita U. Cucurbitacin D isolated from Trichosanthes kirilowii induces apoptosis in human hepatocellular carcinoma cells in vitro. Int Immunopharmacol. 2009;9:508-513. [PMID: 19185617 DOI: 10.1016/j.intimp.2009.01.006] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 2.6] [Reference Citation Analysis]
74 Otsuka M, Kato N, Shao RX, Hoshida Y, Ijichi H, Koike Y, Taniguchi H, Moriyama M, Shiratori Y, Kawabe T, Omata M. Vitamin K2 inhibits the growth and invasiveness of hepatocellular carcinoma cells via protein kinase A activation. Hepatology 2004;40:243-51. [PMID: 15239108 DOI: 10.1002/hep.20260] [Cited by in Crossref: 82] [Cited by in F6Publishing: 71] [Article Influence: 4.6] [Reference Citation Analysis]
75 Liu Z, Zhou Y, Zhang P, Qin H. Meta-analysis of the therapeutic effect of hepatectomy versus radiofrequency ablation for the treatment of hepatocellular carcinoma. Surg Laparosc Endosc Percutan Tech. 2010;20:130-140. [PMID: 20551807 DOI: 10.1097/sle.0b013e3181d823df] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]